These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Antihypertensive treatment in type II diabetes and diabetic nephropathy]. Chantrel F; Bouiller M; Kolb I; Hannedouche T Nephrologie; 2000; 21(2):47-55. PubMed ID: 10798204 [TBL] [Abstract][Full Text] [Related]
26. Should patients with type 2 diabetes focus on glycemic control to reduce their cardiovascular risk? Montori VM Pol Arch Med Wewn; 2008 Sep; 118(9):502-7. PubMed ID: 18846985 [TBL] [Abstract][Full Text] [Related]
27. Intensive diabetes management for high-risk patients: how best to deliver? Marshall SM Diabetes Care; 2009 Jun; 32(6):1132-3. PubMed ID: 19460918 [No Abstract] [Full Text] [Related]
28. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. Donnelly R; Yeung JM; Manning G J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161 [TBL] [Abstract][Full Text] [Related]
29. Reviewing statin therapy in diabetes--towards the best practise. Matikainen N; Kahri J; Taskinen MR Prim Care Diabetes; 2010 Apr; 4(1):9-15. PubMed ID: 20171948 [TBL] [Abstract][Full Text] [Related]
30. Clinical review 51: Implications of the Diabetes Control and Complications Trial. Eastman RC; Siebert CW; Harris M; Gorden P J Clin Endocrinol Metab; 1993 Nov; 77(5):1105-7. PubMed ID: 8077299 [No Abstract] [Full Text] [Related]
31. Fibrates and microvascular complications in diabetes--insight from the FIELD study. Ansquer JC; Foucher C; Aubonnet P; Le Malicot K Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980 [TBL] [Abstract][Full Text] [Related]
32. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Estacio RO; Coll JR; Tran ZV; Schrier RW Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769 [TBL] [Abstract][Full Text] [Related]
33. [Risk and prevention of diabetic nephropathy]. Ravera M; Re M; Deferrari G G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442 [TBL] [Abstract][Full Text] [Related]
34. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780 [TBL] [Abstract][Full Text] [Related]
35. Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. Romero-Aroca P; Fernández-Balart J; Baget-Bernaldiz M; Martinez-Salcedo I; Méndez-Marín I; Salvat-Serra M; Buil-Calvo JA J Diabetes Complications; 2009; 23(4):229-38. PubMed ID: 18439844 [TBL] [Abstract][Full Text] [Related]
36. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years. Hoshi M; Fujita S Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228 [No Abstract] [Full Text] [Related]
37. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. Reichard P; Nilsson BY; Rosenqvist U N Engl J Med; 1993 Jul; 329(5):304-9. PubMed ID: 8147960 [TBL] [Abstract][Full Text] [Related]
38. The effect of pregnancy on the natural history of diabetic retinopathy and nephropathy. Star J; Carpenter MW Clin Perinatol; 1998 Dec; 25(4):887-916. PubMed ID: 9891621 [TBL] [Abstract][Full Text] [Related]
39. Prevention of Microvascular Complications of Diabetes. Crasto W; Patel V; Davies MJ; Khunti K Endocrinol Metab Clin North Am; 2021 Sep; 50(3):431-455. PubMed ID: 34399955 [TBL] [Abstract][Full Text] [Related]